Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study - Takeaways - MDSpire

Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study

  • By

  • Qin Zhang

  • Yi Wang

  • Bingyan Cao

  • Xinmeng Wang

  • Zheng Yuan

  • Xinyu Dou

  • Chunxiu Gong

  • May 29, 2026

  • 0 min

Share

  • 1

    This study analyzed 37 male patients with suspected dual congenital hypogonadotropic hypogonadism receiving GnRH or gonadotropin therapy.

  • 2

    Patients were categorized into favorable and suboptimal early response groups based on testosterone levels and testicular volume changes.

  • 3

    Baseline AMH levels were positively correlated with favorable early responses to treatment, with an odds ratio of 1.977.

  • 4

    The study identified cut-off values for AMH and testosterone after hCG stimulation that demonstrated high sensitivity and specificity.

  • 5

    Findings suggest that early treatment response indicators may help stratify therapy effectiveness, warranting further validation in larger cohorts.

Original Source(s)

Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study

  • by Qin Zhang, Yi Wang, Bingyan Cao, Xinmeng Wang, Zheng Yuan, Xinyu Dou, Chunxiu Gong

  • May 29, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.